Abstract: Antivenoms against snake and scorpion envenomations are usually equine in nature and composed mostly of F(ab`)2; additionally, phenol and m-cresol are mainly employed for their preservation. Although there is no study on this subject, m-cresol is utilized by most manufacturers in a concentration that ranges from 0.15 to 0.35 g%. Decreasing the concentration of m-cresol to its minimal effective level may protect victims from its toxic effects and keep the antivenom stable during its shelf life without forming any aggregates. In the present work, different concentrations of m-cresol, ranging from 0.1 to 0.35 g%, were used with some selected batches of snake and scorpion antivenoms. A low concentration of 0.15 g% showed an acceptable preserving result that complies perfectly with antimicrobial specifications stated by the British Pharmacopoeia. Tested antivenoms (in 12 batches), when kept in a cold room for 39 months (more than their shelf life), retained their physical, chemical and microbiological activities according to the specifications of pharmacopeias. The present data demonstrated that reduction of m-cresol concentration to 0.15 g% in case of equine F(ab`)2 antivenoms will improve safety of such preparations and preserve their stability during their shelf life.
INTRODUCTION
Antivenoms are refined and concentrated preparations of equine serum globulins -mostly F(ab`)2 -obtained by fractionating blood from healthy horses that were previously immunized with different type of venoms (1, 2) . For more than a century, antivenoms have been used effectively as the only treatment for snakebites and envenomations caused by other poisonous animals including spiders and scorpions (3) . Most antivenoms are produced in liquid form to lower their cost and ease their use. Currently, there are eight antimicrobial preservatives commonly used in licensed parenteral products of which m-cresol and phenol are habitually employed by manufacturers as preservatives in antivenom formulations (4) (5) (6) . Usually, phenol concentrations in antivenoms range from 0.15 to 0.5 g% (7) (8) (9) (10) . Combinations of phenol and thimerosal in different ratios have also been effectively used in some antivenom preparations (11, 12) . M-cresol, a phenol derivative, is frequently utilized as preservative in numerous antivenom preparations in concentrations that range between 0.15 and 0.35 g% (4, 7, 13) .
Despite their efficacy as additive, the use of these agents involves the possibility of some adverse effects. It is well known that phenol and cresol are toxic to humans in certain amounts (5, (14) (15) (16) (17) (18) (19) . Repeated exposure may cause harmful effects on the liver and kidney. Additionally, potential development of multiple organ failure with persistence of organ dysfunction associated with the overdose of injectable phenol was already reported (20) . Turbidity, a signal of physical instability in antivenom preparations, increases proportionally to elevation of phenol concentration (6) . Turbidity in equine antivenoms depends, at least, in one way, on the interaction between initial protein concentration in the serum, and addition of phenol during fractionation of serum (10) .
Protein aggregation -besides loss of activity and safety of antivenom -is another important indicator of product instability caused by phenols, which are hydrophobic substances that may induce an increase in protein denaturation (3, 12, 21) . García et al. (12) found differences in the augmentation of aggregate levels and dimmers among antivenoms stored for three years that were devoid of phenol and contained different preservatives, meaning that these substances could accelerate the normal denaturation process.
It is quite curious that such a wide range of preservatives employed in different concentrations in antivenoms was not tested to find the minimum concentration of phenols that may be utilized to restore maximum preserving activity and to maintain stability over the shelf life. In the present study, an attempt was made to optimize the effective preservative concentration in antivenoms by performing a well designed study according to the British Pharmacopoeia (22) . Different types of antivenoms with varying concentrations of m-cresol were used in order to determine the minimum concentration of the mentioned preservative in antivenoms that achieve the best antimicrobial activity. A complete potency and stability study over the real shelf life of antivenom products was carried out to ensure their stability and safety. Meanwhile, improvements in antivenom quality will be focused on the obtainment of a more stable product in compliance with good manufacturing practices and at an affordable quality.
MATERIALS AND METHODS

Materials
Seven batches of polyvalent scorpion antivenom with different m-cresol concentrations -namely 0.0, 0. 
Methods
Determination of Antimicrobial Activity
The method employed followed the one described in the British Pharmacopoeia XVI C 5.1.3 (22) . The test was conducted in sterile capped bacteriological containers. In brief, a series of six containers for each concentration of m-cresol to be examined was inoculated, with a suspension of one of the test microorganisms to give an inoculum of 10 5 to 10 6 microorganisms per milliliter of preparation. The final solution was mixed thoroughly to ensure homogeneous distribution. The inoculated product was incubated at 22.5 ± 2.5°C protected from light. One milliliter of the inoculated sample was removed, at zero, 6 and 24 hours and then at an interval of 7, 14 and 28 days. The number of viable microorganisms was determined by the plate count method. Any residual antimicrobial activity was eliminated by dilution. The initial concentration of viable microorganism in each preparation was estimated based on the concentration of microorganism in each of the standard inoculums as determined by the plate count method.
The antimicrobial activity of each concentration was evaluated in terms of the log reduction in the number of viable microorganisms using as baseline the value obtained for the inoculums.
Product stability over the real shelf lives
One hundred vials from each antivenom batch were kept in cold room at 5 ± 3°C for 39 months protected from light. The quality control tests including pH, sterility, pyrogen, abnormal toxicity, protein concentration, as well as neutralizing potency against lethal activity of different venoms were performed according to the Values represent the mean of six samples followed by their respective standard error of the mean. CFU: colony-forming unit; Nd: not detected.
methods described in the British Pharmacopoeia (22) . Determination of m-cresol concentration was carried out according to method of Bose and Gupta (25) . All tests were performed at zero time and then 39 months after production.
RESULTS
Antimicrobial Activity
In time-matched control experiments, negative control tests were conducted utilizing Values represent the mean of six samples followed by their respective standard error of the mean. CFU: colony-forming unit; Nd: not detected.
microbiological media used for cultivation of different strains of microorganisms. No growth was detected after incubating the media for recommended time and under the recommended conditions. In general, m-cresol in a concentration as low as 0.15 g% provoked complete inhibition of growth in all tested bacterial strains, with both polyvalent scorpion and snake antivenom. This effect was observed during the whole period of the study. The same result was obtained when higher concentrations of the preservative were used with the two types of antivenom (Tables 1,  2 
and 3).
Similar pattern was observed when fungi were used as challenge microorganisms. Low concentrations of m-cresol, (0.15 g% and more) provoked complete growth inhibition of both Aspergilus niger and Candida albicans. The inhibition started 24 hours after incubation and was maintained up to 28 days of the experiment when concentrations of 0.15 and 0.2 g% were used, and at zero time and afterwards when higher m-cresol concentrations were tested (Tables 4 and 5 ). (Table 6 ).
DISCUSSION
Although m-cresol is employed by many antivenom manufacturers as preservative in their preparations, no clear recommendation was found in North American or British pharmacopoeias regarding the actual concentration that should be used to keep the product sterile and stable over the period of its shelf life. This situation gave a good chance for formulators to employ different amounts of the same preservative, sometimes even to a level that may harm the patient. This discrepancy in concentration is clearly observed in most antivenom preparations (9, 10, 12, 26) .
In this study, both polyvalent snake and scorpion antivenoms -containing m-cresol in a concentration of 0.15 g% and more -completely prevented the growth and proliferation of tested microorganisms. This result observes the requirements for the antimicrobial activity stated by the British Pharmacopoeia 2002, which states that the preservative properties of the preparation are adequate if, in the test conditions, there is a significant drop or no increase in the number of microorganisms in the preparation after the evaluation period in adequate conditions. In addition, all antivenom preparations -containing m-cresol in a concentration from 0.15 to 0.25 g% and kept in cold room (at 5 ± 3°C) for more than their real shelf life -did not show any aggregation or other physical instability.
Segura et al. (6) observed that the reduction of phenol to a concentration of 0.15 g% maintains the physical stability of antivenoms and decreases their liability of forming aggregates (6) . Other researchers corroborate such finding, especially if the protein content is elevated, which may lead to loss of antivenom activity and to adverse reactions due to activation of the immune response (4, 21, (26) (27) (28) (29) (30) . At the same time, the decrease of m-cresol concentrations may diminish antivenom toxicity to humans, particularly in certain circumstances in which high doses are required, such as in the two cases mentioned by Buntain (31) and Ganthavorn (32) (750 to 1150 mL of antivenom). Likewise, all quality control tests performed with antivenoms, according to the pharmacopoeial requirements, indicated that their chemical and pharmacological activities were maintained during the whole period of the experiment. Present results also support the conclusion that for maximum protection of patients, the preservative concentration in the final product should be below a level that may be toxic to humans while retaining the product efficiency (33) .
CONCLUSIONS
According to the present study, it is recommended for antivenom producers to reduce m-cresol or phenol to their minimal concentrations to ensure sterility and stability over the real shelf life of the product. At the same time, it is necessary to decrease the toxic load of preservatives, especially if large volumes of antivenoms are required.
